FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to a bispecific anti-4-1BB/anti-EGFR antibody. Also disclosed is a pharmaceutical composition containing said antibody; polynucleotide encoding said antibody; an expression vector containing said polynucleotide; cell for producing said antibody. Disclosed is use of said antibody; method of producing said bispecific antibody.
EFFECT: invention makes it possible to effectively treat cancer with expression of EGFR.
22 cl, 14 dwg, 36 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| BISPECIFIC ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND METHOD FOR PRODUCTION THEREOF | 2021 |
|
RU2818312C1 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| PHARMACEUTICAL COMPOSITION, INCLUDING A PH20 VARIANT OF HUMAN HYALURONIDASE, AND A MEDICINAL PRODUCT FOR SUBCUTANEOUS ADMINISTRATION | 2020 |
|
RU2810952C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
